CAJ | 학술논문

目的探讨安特尔治疗NIH-Ⅲa型前列腺炎合并精液液化延迟的疗效及安全性.方法选取NIH-Ⅲa型前列腺炎合并精液液化延迟患者62例随机分为两组,对照组口服左氧氟沙星0.5mg每天,治疗组加用安特尔40mg每天,疗程1个月.比较治疗前后两组相关指标的变化.结果治疗前两组各项指标无显著差异.治疗后精浆PSA治疗组与对照组分别为1.21±0.46mg/mL和0.83±0.43mg/mL(P=0.002),血清PSA分别为1.79±0.86ng/mL和1.68±0.72ng/mL(P=0.615),血清总睾酮分别为474.83±105.74ng/dl和428.86±106.49ng/dl(P=0.095),NIH-CPSI总分分别为15.76±5.22和16.04±6.22(P=0.853),有效率分别为70.59％和45.83％(P=0.02).结论短期内小剂量安特尔治疗有助于提高精浆PSA水平,促进精液液化,对前列腺炎症状无显著影响.
목적 탐토안특이치료NIH-Ⅲa형전렬선염합병정액액화연지적료효급안전성.방법 선취NIH-Ⅲa형전렬선염합병정액액화연지환자62례수궤분위량조,대조조구복좌양불사성0.5mg매천,치료조가용안특이40mg매천,료정1개월.비교치료전후량조상관지표적변화.결과 치료전량조각항지표무현저차이.치료후정장PSA치료조여대조조분별위1.21±0.46mg/mL화0.83±0.43mg/mL(P=0.002),혈청PSA분별위1.79±0.86ng/mL화1.68±0.72ng/mL(P=0.615),혈청총고동분별위474.83±105.74ng/dl화428.86±106.49ng/dl(P=0.095),NIH-CPSI총분분별위15.76±5.22화16.04±6.22(P=0.853),유효솔분별위70.59％화45.83％(P=0.02).결론 단기내소제량안특이치료유조우제고정장PSA수평,촉진정액액화,대전렬선염증상무현저영향.
Objectives To discuss the effect and safety of Andriol in the treatment of NIH-Ⅲa prostatitis combined with delayed semen liquefaction.Methods 62 patients were enrolled and divided into two groups randomly.The treating group took levofloxacin by 0.5 qd and Andriol by 40mg qd for a month,while the control group took levofloxacin by 0.5 qd only.Data were compared between the two groups.Results The two groups have no difference initially.After the treatment,semen PSA of treating and control groups were 1.21 ±0.46mg/mL and 0.83±0.43mg/mL(P =0.002),serum PSA were 1.79 ±0.86ng/mL and 1.68 ±0.72ng/mL(P =0.615),serum testosterone were 474.83 ± 105.74ng/dl and 428.86 ± 106.49ng/dl(P =0.095),overall NIH-CPSI score were 15.76 ± 5.22 and 16.04 ± 6.22 (P =0.853),improvement rate were 70.59％ and45.83 ％ (P =0.02) respectively.Conclusions Lower dose of Andriol in short term is helpful to improving semen PSA for better liquefaction,and shows no influence in prostatitis symptom.